TY - JOUR
T1 - Molecular analysis of CYP1B1 in Omani patients with primary congenital glaucoma
T2 - A pilot study
AU - El-Gayar, Stefan
AU - Ganesh, Anuradha
AU - Chavarria-Soley, Gabriela
AU - Al-Zuhaibi, Sana
AU - Al-Mjeni, Rayhanah
AU - Raeburn, Sandy
AU - Bialasiewicz, Alexander A.
PY - 2009
Y1 - 2009
N2 - Purpose: To screen cytochrome P4501B1 (CYP1B1) for causative mutations in Omani patients with a clinical diagnosis of primary congenital glaucoma (PCG). Methods: Nine PCG families were recruited for the study. All patients underwent detailed clinical examinations to confirm the diagnosis of PCG. The families of index patients were also examined. Genealogical information was obtained by pedigree analysis. The primary candidate gene, CYP1B1, was amplified from genomic DNA, sequenced, and analyzed in patients to identify the disease-causing mutations. Results: Eight of the nine PCG families were consanguineous (89%). Molecular analysis of CYP1B1 showed three distinct mutations, p.G61E, p.D374N, and p.R368H, in seven of nine unrelated PCG index patients (78%). Six patients had homozygous mutations and one had a compound heterozygous mutation. Causative mutations were not identified in two families. In family 4, the index patient was found to be heterozygous for the p.E229K variant. In family 6, although affected individuals were found to be homozygous in the CYP1B1 region, no mutation could be identified. Conclusions: This study indicates that CYP1B1 could be the predominant cause of PCG in the Omani population (78%). Omani PCG patients show allelic heterogeneity. Further studies are needed to delineate the spectrum of CYP1B1 mutations in Omani PCG families and to identify new or modifier genes contributing to the manifestations of PCG in this region.
AB - Purpose: To screen cytochrome P4501B1 (CYP1B1) for causative mutations in Omani patients with a clinical diagnosis of primary congenital glaucoma (PCG). Methods: Nine PCG families were recruited for the study. All patients underwent detailed clinical examinations to confirm the diagnosis of PCG. The families of index patients were also examined. Genealogical information was obtained by pedigree analysis. The primary candidate gene, CYP1B1, was amplified from genomic DNA, sequenced, and analyzed in patients to identify the disease-causing mutations. Results: Eight of the nine PCG families were consanguineous (89%). Molecular analysis of CYP1B1 showed three distinct mutations, p.G61E, p.D374N, and p.R368H, in seven of nine unrelated PCG index patients (78%). Six patients had homozygous mutations and one had a compound heterozygous mutation. Causative mutations were not identified in two families. In family 4, the index patient was found to be heterozygous for the p.E229K variant. In family 6, although affected individuals were found to be homozygous in the CYP1B1 region, no mutation could be identified. Conclusions: This study indicates that CYP1B1 could be the predominant cause of PCG in the Omani population (78%). Omani PCG patients show allelic heterogeneity. Further studies are needed to delineate the spectrum of CYP1B1 mutations in Omani PCG families and to identify new or modifier genes contributing to the manifestations of PCG in this region.
UR - http://www.scopus.com/inward/record.url?scp=67650514321&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67650514321&partnerID=8YFLogxK
M3 - Article
C2 - 19597567
AN - SCOPUS:67650514321
SN - 1090-0535
VL - 15
SP - 1325
EP - 1331
JO - Molecular Vision
JF - Molecular Vision
ER -